Celiac Disease - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 85
Inquire Before Buying

Celiac Disease - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2018, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape.

Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogren's syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 9 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Celiac Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Celiac Disease - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
Amgen Inc
Calypso Biotech SA
IB Pharmaceuticals Inc
ImmusanT Inc
Intrexon Corp
Takeda Pharmaceutical Co Ltd
Topas Therapeutics GmbH
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVX-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEN-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Product Development Milestones
Featured News & Press Releases
May 24, 2018: ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention
May 21, 2018: ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development
May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
May 15, 2018: ImmusanT Welcomes Ken Truitt as Chief Medical Officer
May 15, 2018: ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer
May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
Jan 08, 2018: Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA
Jan 04, 2018: ImmusanT Provides Year-End Update and Outlines Goals for 2018
Nov 28, 2017: ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies
Oct 31, 2017: ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease
Oct 25, 2017: ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data at United European Gastroenterology Week
Oct 12, 2017: ImmusanT to Present New Nexvax2 Dosing Data at United European Gastroenterology Week
Sep 13, 2017: Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis
Sep 11, 2017: ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax2
Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Celiac Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Celiac Disease - Pipeline by Amgen Inc, H2 2018
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2018
Celiac Disease - Pipeline by IB Pharmaceuticals Inc, H2 2018
Celiac Disease - Pipeline by ImmusanT Inc, H2 2018
Celiac Disease - Pipeline by Intrexon Corp, H2 2018
Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2018
Celiac Disease - Pipeline by Zedira GmbH, H2 2018
Celiac Disease - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Celiac Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Enterocolitis - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 41
    Enterocolitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Enterocolitis - Pipeline Review, H2 2018, provides an overview of the Enterocolitis (Gastrointestinal) pipeline landscape. Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include Inf......
  • Eosinophilic Esophagitis - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 85
    Eosinophilic Esophagitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2018, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape. Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation ......
  • Gastroenteritis - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 88
    Gastroenteritis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H2 2018, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape. Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact wit......
  • Global Exocrine Pancreatic Insufficiency Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 10-Oct-2018        Price: US 3480 Onwards        Pages: 130
    Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas. Scope of the Report: This report studies the Exocrine Pancreatic Insufficiency market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Exocrine Pancreatic Insufficiency market......
  • Global Irritable Bowel Syndrome (IBS) Market Insights, Forecast to 2025
    Published: 08-Oct-2018        Price: US 3900 Onwards        Pages: 112
    This report studies the global market size of Irritable Bowel Syndrome (IBS) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Irritable Bowel Syndrome (IBS) in these regions. This research report categorizes the global Irritable Bowel Syndrome (IBS) market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, gro......
  • Global Inflammatory Bowel Disease Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the inflammatory bowel disease partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Inflammatory Bowel Disease Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnerin......
  • Global Gastrointestinal Symptoms Partnering 2012 to 2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the gastrointestinal symptom partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Gastrointestinal Symptoms Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering d......
  • Global Irritable Bowel Syndrome Partnering 2012-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the irritable bowel syndrome partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Irritable Bowel Syndrome Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering de......
  • Global Esophageal Reflux Partnering 2012-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Provides understanding and access to the esophageal reflux partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Esophageal Reflux Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - T......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs